HSINCHU, Taiwan and WUHAN, China, Feb. 3, 2018 – JHL Biotech (TPEx: 6540) announced that the Taipei Exchange (“TPEx”) granted approval on February 2 for the termination of trading of JHL's shares on the Emerging Stock Market of TPEx. JHL had submitted an application to voluntarily delist from TPEx. JHL's Board of Directors believes this is in the best interests of the company and its shareholders because it enables JHL to pursue planned expansion activities and to explore various fundraising strategies (including potentially listing on an overseas exchange).
TPEx granted approval via Approval Letter No.: 10700029171. JHL shares will cease to trade on the Emerging Stock Market of TPEx as of February 17, 2018. During the period from February 17, 2018 to April 7, 2018, JHL will purchase the shares eligible for sale at the price of NT$63 per share, pursuant to relevant laws.
About JHL Biotech
JHL Biotech, Inc. is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech's mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL is developing proposed biosimilars to rituximab, dornase alfa, bevacizumab, and trastuzumab. JHL1101, JHL's proposed rituximab biosimilar, is undergoing clinical trials in the European Union. In addition to biosimilars, JHL also co-develops innovative new molecules and provides contract manufacturing services to select clients. JHL has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. For more information, please visit www.jhlbiotech.com.
This press release contains forward-looking statements. Statements in this press release are not historical facts, including but not limited to the statements regarding JHL's future plans and its ability to complete the proposed Voluntary Delisting and maximize shareholder value, represent only the current expectations, assumptions, estimates and projections of the Company and are forward-looking statements. These forward-looking statements involve various risks and uncertainties. Important risks and uncertainties that could cause the actual results to be materially different from expectations include but are not limited to, capital markets conditions. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
View original content with multimedia:http://www.prnewswire.com/news-releases/jhl-biotechs-application-to-voluntarily-terminate-trading-of-shares-approved-by-taipei-exchange-300593030.html
SOURCE JHL Biotech, Inc.
Latest posts by Editorial Team (see all)
- American Academy of Thermology 2018 Annual Scientific Session Awarded 6.5 hours of AMA PRA Category 1 CME - May 20, 2018
- Strong Programme Raises Profile of the Maritime Standard Ship Finance and Trade Conference - May 20, 2018
- Pegasus Food Futures Announces Appointment of Stefanie Paterson as Head of Human Resources - May 20, 2018